The estimated Net Worth of Shawn Singh is at least 2.91 百万$ dollars as of 17 August 2022. Mr. Singh owns over 600,000 units of Vistagen Therapeutics stock worth over 1,972,637$ and over the last 8 years he sold VTGN stock worth over 0$. In addition, he makes 933,667$ as Chief Executive Officer、 Director at Vistagen Therapeutics.
Shawn has made over 4 trades of the Vistagen Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 600,000 units of VTGN stock worth 102,000$ on 17 August 2022.
The largest trade he's ever made was buying 600,000 units of Vistagen Therapeutics stock on 17 August 2022 worth over 102,000$. On average, Shawn trades about 29,215 units every 52 days since 2016. As of 17 August 2022 he still owns at least 626,234 units of Vistagen Therapeutics stock.
You can see the complete history of Mr. Singh stock trades at the bottom of the page.
Shawn K. Singh J.D. serves as Chief Executive Officer, Director of the Company. Mr. Singh has served as our Chief Executive Officer since August 2009, first as the Chief Executive Officer of VistaGen Therapeutics, Inc., a California corporation (VistaGen California), then as Chief Executive Officer of the Company after the Merger. Mr. Singh first joined the Board of Directors of VistaGen California in 2000 and served on the VistaGen California management team (part-time) from late-2003, following VistaGen California’s acquisition of Artemis Neuroscience, of which he was President, to August 2009. In connection with the Merger, Mr. Singh was appointed as a member of our Board in 2011. Mr. Singh has nearly 30 years of experience working with biotechnology, medical device and pharmaceutical companies, both private and public. From 2001 to August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, a life science venture capital firm, and as Chief Business Officer and General Counsel of Cato Research Ltd, a contract research organization (CRO) affiliated with Cato BioVentures. Mr. Singh served as President (part-time) of Echo Therapeutics, a medical device company, from 2007 to 2009, and as a member of its Board of Directors from 2007 to 2011. He also served as Chief Executive Officer (part-time) of Hemodynamic Therapeutics, a private biopharmaceutical company affiliated with Cato BioVentures, from 2004 to 2009. From 2000 to 2001, Mr. Singh served as Managing Director of Start-Up Law, a management consulting firm serving biotechnology companies. Mr. Singh also served as Chief Business Officer of SciClone Pharmaceuticals (formerly NASDAQ: SCLN), a specialty pharmaceutical company with a substantial commercial business in Greater China, from 1993 to 2000, and as a corporate finance associate of Morrison & Foerster LLP, an international law firm, from 1991 to 1993. Mr. Singh earned a B.A. degree, with honors, from the University of California, Berkeley.
As the Chief Executive Officer、 Director of Vistagen Therapeutics, the total compensation of Shawn Singh at Vistagen Therapeutics is 933,667$. There are no executives at Vistagen Therapeutics getting paid more.
Shawn Singh is 57, he's been the Chief Executive Officer、 Director of Vistagen Therapeutics since 2018. There are 10 older and 5 younger executives at Vistagen Therapeutics. The oldest executive at Vistagen Therapeutics Inc. is Jon Saxe, 84, who is the Independent Chairman of the Board.
Shawn's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 8 years, insiders at Vistagen Therapeutics have traded over 147,300$ worth of Vistagen Therapeutics stock and bought 1,944,506 units worth 18,208,989$ . The most active insiders traders include Healthcare Capital Partners...、Capital Lp Commodore、Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of 378,372$. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth 17,958,751$.
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Vistagen Therapeutics executives and other stock owners filed with the SEC include: